Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein

Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein
Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one of the most important targets for therapies to alleviate the conditions. The patent is the third Protagonist has obtained for the inhibitors. The others can be found here and here. Protagonist is conducting a global Phase 2b clinical trial (NCT02895100) to assess PTG-100 capsules' ability to improve moderate to severe ulcerative colitis. The 240 patients are receiving one of three doses of PTG-100 a day — 150, 300 or 900 mgs — or a placebo, for 12 weeks. Researchers are still recruiting participants. "These new patents further strengthen the long-term intellectual property protection for these clinical-stage assets, both of which have emerged from our innovative peptide technology platform," Dr. Dinesh Patel, the president and CEO of Protagonist, said in a press release. In a related development, Protagonist announced a second patent on its development of synthetic peptides that can mimic hepcidin, a hormone that regulates the body's iron levels. A peptide is a small protein. These peptides, which include PTG-300, are designed to regulate iron diso
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *